The role of TLR4 in liver disease is well established as an activator of obesity-associated inflammation and insulin resistance, thus serving as a therapeutic target for the treatment of type 2 diabetes (Jia et al., 2014). This evidence concerns the gene TLR4 and obesity due to melanocortin 4 receptor deficiency.